PIPELINES
Neovascular Aged-related Macular Degeneration (nAMD)
According to the World Health Organisation (WHO), around 196 million people were affected by age-related macular degeneration (AMD) globally in 2020, including over 10.4 million moderate-to-severe vision impairment cases.
Current anti-VEGFs treatment drugs – Lucentis (Ranibizumab) and Eylea (Aflibercept), reported global sales in 2021 of US$3.64bn and US$9.38bn respectively.
Dry Eye Disease (DED)
An article published in the Journal of the British College of Ophthalmic Opticians stated that the global prevalence of dry eye disease (DED) was estimated at 11.59% in 2021.
Current prescribed treatment drugs – Restasis (cyclosporine, Allergen) and Xiidra (lifitegrast, Novartis) reported global sales in 2021 of US$1.29bn and US$460m respectively.
Bio-compatible Cornea
Corneal visual impairment encompasses a wide variety of infectious and inflammatory eye diseases that cause scarring of the cornea. Significant scarring ultimately leads to functional vision loss. It is the 4th cause of blindness globally, after cataract, glaucoma and nAMD, as indicated by World Health Organization (WHO).
“SwitchGene” Gene Therapy
“SwitchGene” is a novel approach to the treatment of ocular neovascularisation with the potential to eliminate the requirement for regular IVT injections and for controlling the level of VEGF activity on an individualised basis. It also has potential for treating other VEGF-aberrant ocular diseases including but not limited to Diabetic Retinopathy (DR).
Our Planned Pipeline Projects
